HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company’s growing body of clinical evidence, including collaborations with leading institut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. (Exact name of Registrant as specified in its charter) | Delaware | 27-5566468 | | --- | -- ...

HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipeline, support ...

HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and othe ...

HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock at a price to the public of $1.30 per share. The gross proceeds from the offering to Nexalin are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and other offering ...

Core Viewpoint - Nexalin Technology, Inc. is initiating formal regulatory engagement with the FDA for its Gen-2 SYNC system, aimed at treating Alzheimer's disease, dementia, and mild cognitive impairment (MCI) [1][2]. Regulatory Engagement - The company plans to submit a Q-Submission ("Q-Sub") to the FDA to facilitate structured dialogue regarding clinical trial design [1][2]. - This decision follows recent publications, encouraging internal data, and preliminary feedback from the FDA, marking a critical step in advancing Gen-2 SYNC as a non-invasive therapeutic option [2]. Product Development - The Gen-2 SYNC system features technical enhancements over prior generations, including a redesigned enclosure and a proprietary 15 milliamp advanced waveform [3]. - The company is rebranding the device to clearly differentiate it from earlier versions, marketing it as "Gen-2 SYNC" [3]. Company Focus - Nexalin is committed to progressing regulatory engagement and advancing its neuromodulation platform as a promising therapeutic alternative for cognitive and neuropsychiatric disorders [3]. - The company designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology [5].

Core Insights - Nexalin Technology, Inc. has successfully completed and launched phases one through five of its proprietary virtual clinic and digital research ecosystem, which supports data capture, remote monitoring, and virtual treatment with its HALO™ headset [1][2][3] Group 1: Virtual Clinic Launch - The virtual clinic was launched at the University of California, San Diego (UCSD) to facilitate patient recruitment for a military study on TBI/PTSD [1] - The platform enables real-time data capture and clinical oversight, allowing patients to receive treatment in their homes while ensuring compliance with research protocols [1][2] Group 2: Digital Infrastructure - Nexalin has established a comprehensive digital infrastructure that includes an AI-integrated Electronic Data Capture (EDC) platform and a Patient Monitoring System (PMS) [2][7] - This infrastructure enhances capabilities for remote research studies and streamlines patient care using non-invasive DIFS™ technology [2][4] Group 3: Clinical Research and Treatment - The virtual clinic facilitates clinical research on the HALO™ device, focusing on mental health disorders, traumatic brain injury, addiction, and neurodegenerative conditions [3][4] - The system allows for remote monitoring of treatment adherence and tracking of patient outcomes, optimizing clinical protocols [4][7] Group 4: Future Prospects - The completion of the virtual clinic positions Nexalin to expand research collaborations, advance regulatory approvals, and accelerate commercialization efforts for HALO™ and future DIFS™ technology applications [4]

Core Viewpoint - Nexalin Technology, Inc. has received a patent for its Deep Intracranial Frequency Stimulation (DIFS™) technology, which aims to provide a non-invasive and drug-free treatment for substance use disorders, including opioid use disorder and alcohol use disorder [1][2][3] Company Overview - Nexalin Technology focuses on developing innovative neurostimulation products to address the global mental health crisis, utilizing bioelectronic medical technology to treat mental health issues [5] - The company's DIFS™ technology is designed to regulate neural pathways associated with addiction and withdrawal symptoms, potentially improving treatment outcomes for individuals with substance use disorders [1][2] Patent Significance - The patent granted by the USPTO for the "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder and Substance Use Disorder" enhances Nexalin's intellectual property portfolio and validates the innovative nature of its DIFS™ technology [1][3] - This patent is seen as a significant achievement for the company, reinforcing its position as a pioneer in non-invasive brain stimulation for addiction and mental health therapy [2][3] Market Context - Substance use disorders, including opioid dependency and alcoholism, represent a major public health challenge globally, with traditional treatment methods often facing issues of accessibility and side effects [2] - Nexalin's DIFS™ technology offers a forward-thinking alternative to conventional therapies, aiming to alleviate withdrawal symptoms and support long-term recovery without the risks associated with pharmaceutical treatments [2][3]

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™. This significa ...

Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin ...